Formulary forum: Exenatide: A new option for the treatment of type 2 diabetes
C th hi kin bc s trc khi b b qun liu, khng t ung tng liu
Thanks for sharing your story, Tracy
Diabetes Care 2010;33:951957
Lu 4 , Nicholas Davidson 5 and Jos M Mato 2,6 , (1)OWL Metabolomics, Derio, Spain, (2)CIC Biogune, Basque Research and Technology Alliance (BRTA), Derio, Spain, (3)Houston Research Institute, Houston, TX, (4)Cedars-Sinai Medical Center, Los Angeles, CA, (5)Washington University Medical School, Departments of Medicine and Molecular Biology and Pharmacology, Saint Louis, MO, (6)National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Madrid, Spain Background: Non-alcoholic fatty liver disease (NAFLD) affects individuals worldwide
It enhances cell migration and angiogenesis (the formation of new blood vessels), making it key for broader tissue healing